A randomized trial of dexamethasone before remission induction, in de novo childhood acute lymphoblastic leukemia

We evaluated the impact of adding dexamethasone before chemotherapy in 95 children with de novo standard-risk acute lymphoblastic leukemia (ALL). The children were randomly divided into 2 groups: one group was given dexamethasone, the other was not. The initial characteristics and mean follow-up of...

Full description

Saved in:
Bibliographic Details
Published inHaematologica (Roma) Vol. 89; no. 3; pp. 365 - 366
Main Authors Lopez-Hernandez, MA, Alvarado, M, De Diego, J, Borbolla-Escoboza, , JR, Jimenez, RM, Trueba, E
Format Journal Article
LanguageEnglish
Published Italy 01.03.2004
Subjects
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Child
Dexamethasone - administration & dosage
Drug Administration Schedule
Female
Humans
Male
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Remission Induction
Online AccessGet full text

Cover

More Information
Summary:We evaluated the impact of adding dexamethasone before chemotherapy in 95 children with de novo standard-risk acute lymphoblastic leukemia (ALL). The children were randomly divided into 2 groups: one group was given dexamethasone, the other was not. The initial characteristics and mean follow-up of both groups were similar. Day +14 blast percentage was significantly lower in the dexamethasone group. Disease-free survival at 40-months follow-up was better (almost significantly so) in the dexamethasone group.
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
ObjectType-Feature-1
ObjectType-Correspondence-3
content type line 66
ObjectType-News-4
ISSN:0390-6078
1592-8721